Focused On-demand Library for C-C motif chemokine 23

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P55773

UPID:

CCL23_HUMAN

Alternative names:

CK-beta-8; Macrophage inflammatory protein 3; Myeloid progenitor inhibitory factor 1; Small-inducible cytokine A23

Alternative UPACC:

P55773; B7ZKQ3; O00174; O75950; Q52LD4

Background:

C-C motif chemokine 23 (CCL23), also known as CK-beta-8, Macrophage inflammatory protein 3, and Myeloid progenitor inhibitory factor 1, plays a crucial role in immune responses. It exhibits chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils, while not affecting activated lymphocytes. Additionally, CCL23 inhibits the proliferation of myeloid progenitor cells and can bind to heparin and CCR1. Its truncated forms, such as CCL23(19-99), show enhanced chemoattractant properties.

Therapeutic significance:

Understanding the role of C-C motif chemokine 23 could open doors to potential therapeutic strategies, especially in modulating immune responses and treating conditions involving myeloid cells.